Skip to content
Preprint · CC-BY via OpenAlex

Targeting senescence in Amyotrophic Lateral Sclerosis: senolytic treatment improves neuromuscular function and preserves cortical excitability in a TDP-43Q331K mouse model.

Jose A. Viteri*, Nathan R. Kerr*, Charles D. Brennan*, Grace Robinson Kick, Meifang Wang, Arsh Haj Mohamad Ebrahim Ketabforoush, Harper K. Snyder, Peter J. Moore, Fereshteh B. Darvishi, Anna Roshani Dashtmian, Sindhuja N. Ayyagari, Kelly A. Rich, Yi Zhun Zhu, W. David Arnold

Research Square · 2025 · ▲ 1 citations

Abstract

Abstract Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder marked by progressive motor neuron degeneration in the primary motor cortex (PMC) and spinal cord. Aging is a key factor in ALS onset and progression, with evidence suggesting that biological aging—a process involving cellular decline— far outpaces chronological aging in ALS. This promotes senescent cell accumulation—marked by irreversible cell-cycle arrest, impaired apoptosis, and chronic inflammation—disrupting tissue homeostasis and impairing neuronal support functions. Thus, targeting senescence(definition) presents a novel therapeutic strategy for ALS. Here, we investigated the senolytic combination Dasatinib and Quercetin (D&Q) in TDP-43 Q331K ALS mice. D&Q improved neuromuscular function and reduced plasma neurofilament light chain, a biomarker of axonal damage. The most pronounced improvement was the improved cortical excitability, accompanied by reductions in senescence and TDP-43 in the PMC. These findings highlight the potential of senolytics(definition) to mitigate ALS-related dysfunction, supporting their viability as a therapeutic strategy. *Jose A. Viteriab, Nathan R. Kerrab, and Charles D. Brennana are co-first authors.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
OpenAlex
DOI
10.21203/rs.3.rs-6081213/v1
Canonical
link ↗
Fetched
2026-11-01 MST

Cite this

APA
Viteri*, J.A., Kerr*, N.R., Brennan*, C.D., Kick, G.R., Wang, M., Ketabforoush, A.H.M.E., Snyder, H.K., Moore, P.J., Darvishi, F.B., Dashtmian, A.R., Ayyagari, S.N., Rich, K.A., Zhu, Y.Z., &amp; Arnold, W.D. (2025). Targeting senescence in Amyotrophic Lateral Sclerosis: senolytic treatment improves neuromuscular function and preserves cortical excitability in a TDP-43Q331K mouse model. <em>Research Square</em>. https://doi.org/10.21203/rs.3.rs-6081213/v1
Vancouver
Viteri* JA, Kerr* NR, Brennan* CD, Kick GR, Wang M, Ketabforoush AHME, et al. Targeting senescence in Amyotrophic Lateral Sclerosis: senolytic treatment improves neuromuscular function and preserves cortical excitability in a TDP-43Q331K mouse model. Research Square. 2025. doi:10.21203/rs.3.rs-6081213/v1.
BibTeX
@unpublished{jose2025Target, title = {Targeting senescence in Amyotrophic Lateral Sclerosis: senolytic treatment improves neuromuscular function and preserves cortical excitability in a TDP-43Q331K mouse model.}, author = {Jose A. Viteri* and Nathan R. Kerr* and Charles D. Brennan* and Grace Robinson Kick and Meifang Wang and Arsh Haj Mohamad Ebrahim Ketabforoush and Harper K. Snyder and Peter J. Moore and Fereshteh B. Darvishi and Anna Roshani Dashtmian and Sindhuja N. Ayyagari and Kelly A. Rich and Yi Zhun Zhu and W. David Arnold}, journal = {Research Square}, year = {2025}, doi = {10.21203/rs.3.rs-6081213/v1}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings